AC Immune acquires Parkinson’s disease vaccine candidate and equity investment

AC Immune acquires Parkinson’s disease vaccine candidate and equity investment

28.7.2021 – With the acquisition of Affiris PD01, AC Immune strengthens its position in the development of therapeutics and diagnostics for Parkinson’s diseases. The company will immediately launch a phase 2 study of the acquired vaccine. Additionally, the company secured USD 25 million in a private placement led by premier investor Athos Service.

read more in startupticker